TransMedics Group stock has delivered a strong 153.4% gain over the past five years, yet its recent share price weakness and current valuation checks suggest the stock may still be pricing in less than its full potential rather than looking stretched.

• Over five years, TransMedics Group has returned 153.4%, which puts the recent pullback into context as a pause after a strong longer term run.
• Expectations around TransMedics Group's ability to grow transplant procedure volumes can support the valuation, while any setbacks in adoption or pressure on procedure economics may weigh on what investors are willing to pay.
• On Simply Wall St's broader checks, TransMedics Group screens as undervalued in most areas, with a value score of 5 out of 6, which points to multiples that still look attractive relative to fundamentals.

The issue now is whether the recent share price weakness in TransMedics Group offers a relatively cheap entry based on those valuation checks, or if the stock's longer term gains already capture most of the opportunity.

Does TransMedics Group Look Undervalued on Earnings?

The P/E multiple fits TransMedics Group well because earnings are a key focus for many investors in medical technology businesses. On this basis, TransMedics Group trades on a P/E of about 14.5x, which is well below the Medical Equipment industry average of roughly 26.7x and also below a broader peer average of around 40.2x. That puts the stock at a sizeable discount to many companies operating in similar areas.

Simply Wall St’s fair P/E for TransMedics Group, which blends factors such as growth expectations, margins, size and risk, sits at about 24.4x. Compared with the current 14.5x, the market is applying a lower multiple than this model suggests, leaving a wide gap between the trading P/E and the level implied by those fundamentals. For investors, that gap is the key reason the stock appears attractively priced on an earnings basis.

On the P/E multiple, TransMedics Group stock appears undervalued relative to both its tailored fair ratio and typical industry levels.

The TransMedics Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for TransMedics Group sit between the current P/E puzzle and what might happen next by spelling out which paths for TransMedics Group's growth, margins and earnings would line up with a higher or lower share price than today. Instead of giving a single output like a ratio or model, they unpack the future those numbers rely on so you can watch whether that story actually plays out over time. These narratives are available on Simply Wall St's Community page.

One of the top community narratives on TransMedics Group: 10% undervalued

"Sustained high R&D, expansion, and logistics infrastructure costs, especially as the company invests heavily in new headquarters, aviation fleet, and next-gen clinical programs, could outpace actual revenue growth..."

Do you think there's more to the story for TransMedics Group? Head over to our Community to see what others are saying!

The Bottom Line

For now, TransMedics Group screens as undervalued on earnings-based multiples, with the current P/E sitting well below both industry and tailored fair-value benchmarks. That discount reflects a market that is still cautious about how reliably transplant volumes, margins and capital spending can translate into durable earnings. The key question from here is whether TransMedics Group can execute on procedure growth and cost control strongly enough for the multiple to move closer to peers, or whether the current discount proves to be the market correctly pricing the execution risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.